Blood advances 2023 Jul 25
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes.
Related Questions
New answer by at University of Chicago (March 26, 2024)
A trial of luspatercept would be a reasonable option for this patient. While the phase III studies supporting the use of luspatercept do not represent this patient (MEDALIST F...